The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
In a randomized clinical trial, a team of researchers compared the use of cefepime and piperacillin-tazobactam—commonly used medications for empirical treatment of infection—to determine the risks of...
Did you watch our Multidisciplinary Roundtable on managing nutrition in patients with chronic kidney disease? Here are some highlights that you may have missed.
The FDA approves the first-of-its-kind treatment for anemia caused by CKD for adults who receive dialysis following the results of a randomized clinical trial.
The Work Group from the Kidney Disease: Improving Global Outcomes organization updated its set of guidelines that offers clinical practice guidelines in the treatment of chronic kidney disease and...
In order to examine the effects of probiotic, prebiotic, and synbiotic supplementation in patients with CKD, the researchers conducted a systematic review and meta-analysis of 13 randomized controlled...
To address a lack of lifestyle recommendations for CKD prevention, researchers conducted an evaluation of data from 104 studies of 2,755,719 adults without CKD at baseline which reported on lifestyle...
